Atara Biotherapeutics Inc (ATRA) CFO John Mcgrath Sells 13,000 Shares

Atara Biotherapeutics Inc (NASDAQ:ATRA) CFO John Mcgrath sold 13,000 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $47.07, for a total transaction of $611,910.00. Following the completion of the transaction, the chief financial officer now directly owns 99,056 shares of the company’s stock, valued at approximately $4,662,565.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

John Mcgrath also recently made the following trade(s):

  • On Friday, January 12th, John Mcgrath sold 37,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $24.35, for a total transaction of $900,950.00.
  • On Friday, December 29th, John Mcgrath sold 32,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $640,000.00.
  • On Friday, December 29th, John Mcgrath sold 32,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $640,000.00.

Atara Biotherapeutics Inc (ATRA) opened at $44.80 on Wednesday. Atara Biotherapeutics Inc has a fifty-two week low of $11.80 and a fifty-two week high of $49.90.

Institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new position in shares of Atara Biotherapeutics during the third quarter worth $142,000. Russell Investments Group Ltd. purchased a new position in Atara Biotherapeutics in the third quarter valued at $170,000. Voya Investment Management LLC increased its holdings in Atara Biotherapeutics by 16.2% in the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 1,651 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in Atara Biotherapeutics in the fourth quarter valued at $217,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Atara Biotherapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after buying an additional 1,369 shares in the last quarter. 74.29% of the stock is owned by hedge funds and other institutional investors.

ATRA has been the subject of several recent research reports. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a report on Friday, December 29th. ValuEngine raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 6th. BidaskClub raised shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 23rd. Finally, Cowen initiated coverage on shares of Atara Biotherapeutics in a report on Friday, January 26th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $30.60.

TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/21/atara-biotherapeutics-inc-atra-cfo-john-mcgrath-sells-13000-shares.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply